December 2005
Feature: 2005 in Review - Beauties and the Beasts.
December 21, 2005
Feature: 2005 in Review - Beauties and the Beasts. I’m not going to belabor the fact that the Santa rally hasn’t materialized for the smallcaps this year. As a matter of fact, the fall pretty much sucked out loud for the genre. Along with some good wins, along with everyone else, we also took some lumps...
Feature: 2005 in Review - Beauties and the Beasts. I’m not going to belabor the fact that the Santa rally hasn’t materialized for the smallcaps this year. As a matter of fact, the fall pretty much sucked out loud for the genre. Along with some good wins, along with everyone else, we also took some lumps...
Trading Alert: Elephant Hunting for '06 Gains.
December 17, 2005
Trading Alert: Elephant Hunting for '06 Gains. Investing at this time of year tends to be an enigma. Visions of Santa rallies, tax loss selling and quadruple witching—such as Friday—dance in investors’ heads, making trading activity both a blessing and a curse. We looked around for three big cap names...
Trading Alert: Elephant Hunting for '06 Gains. Investing at this time of year tends to be an enigma. Visions of Santa rallies, tax loss selling and quadruple witching—such as Friday—dance in investors’ heads, making trading activity both a blessing and a curse. We looked around for three big cap names...
Feature: Slick Oil Trading. Forget the Long-Term.
December 14, 2005
Feature: Slick Oil Trading. Forget the Long-Term. On November 12th, as everyone was calling for an oil rally, we noted that oil was more likely to drop to $56.50 prior to any renewed price rise. A few days later the price dropped a bit past our projected level and bingo, the rally resumed. Of course...
Feature: Slick Oil Trading. Forget the Long-Term. On November 12th, as everyone was calling for an oil rally, we noted that oil was more likely to drop to $56.50 prior to any renewed price rise. A few days later the price dropped a bit past our projected level and bingo, the rally resumed. Of course...
Feature: Rally Rockin' or Rolling Over? Guilty Market Pleasures.
December 08, 2005
Feature: Rally Rockin' or Rolling Over? Guilty Market Pleasures. Prior to what has become my annual pilgrimage to Las Vegas—I like to lose early so I can enjoy the rest of the trip—I thought it would be prudent to look at the markets; especially since we have been calling this recent rally correctly...
Feature: Rally Rockin' or Rolling Over? Guilty Market Pleasures. Prior to what has become my annual pilgrimage to Las Vegas—I like to lose early so I can enjoy the rest of the trip—I thought it would be prudent to look at the markets; especially since we have been calling this recent rally correctly...
Feature: Novelos - FDA Green Lights Phase 3 Cancer Study.
December 05, 2005
Feature: Novelos - FDA Green Lights Phase 3 Cancer Study. The title of today’s release (below) from biotech Novelos Therapeutics (OTCBB: NVLT) speaks volumes: “Novelos Therapeutics Gets Green Light From FDA For Phase 3 Development in Lung Cancer”. Obviously the FDA saw the value of continuing the regulatory...
Feature: Novelos - FDA Green Lights Phase 3 Cancer Study. The title of today’s release (below) from biotech Novelos Therapeutics (OTCBB: NVLT) speaks volumes: “Novelos Therapeutics Gets Green Light From FDA For Phase 3 Development in Lung Cancer”. Obviously the FDA saw the value of continuing the regulatory...
Feature: Biophan - Good for Hearts...Great for Portfolios.
December 02, 2005
Feature: Biophan - Good For Hearts...Great for Portfolios. The late entrepreneur Victor Kiam came to fame and fortune with the phrase: “I liked the product so much, I bought the company”. Mr. Kiam would certainly have approved of next generation medical device company Biophan’s (OTCBB: BIPH) announcement...
Feature: Biophan - Good For Hearts...Great for Portfolios. The late entrepreneur Victor Kiam came to fame and fortune with the phrase: “I liked the product so much, I bought the company”. Mr. Kiam would certainly have approved of next generation medical device company Biophan’s (OTCBB: BIPH) announcement...
November 2005
Feature: Novelos/FDA Meet Friday. DOW 11,000?
November 29, 2005
Feature: Novelos/FDA Meet Friday. DOW 11,000? As we mentioned on November 8th, biotech Novelos (OTCBB: NVLT) meets with the FDA on December 2nd to discuss its impressive Phase 1/2 results for its NOV-002 treatment for non-small call lung cancer (NSCLC). The company’s intention is to get the green light...
Feature: Novelos/FDA Meet Friday. DOW 11,000? As we mentioned on November 8th, biotech Novelos (OTCBB: NVLT) meets with the FDA on December 2nd to discuss its impressive Phase 1/2 results for its NOV-002 treatment for non-small call lung cancer (NSCLC). The company’s intention is to get the green light...
Feature: Gold on Fire - Going Higher?
November 23, 2005
Feature: Gold on Fire - Going Higher? Until recently, most investors couldn’t tell you the gold price to within $50. Now, just about everyone knows it’s flirting with $500 an ounce. Is a pullback of this nifty move coming? Maybe. In the Q3 2005, there are a few factors investors should know about what’s...
Feature: Gold on Fire - Going Higher? Until recently, most investors couldn’t tell you the gold price to within $50. Now, just about everyone knows it’s flirting with $500 an ounce. Is a pullback of this nifty move coming? Maybe. In the Q3 2005, there are a few factors investors should know about what’s...
Feature: Go-Time for Time Warner. Trading on Insider Information.
November 18, 2005
Feature: Go-Time for Time Warner? Trading on Insider Information. Investors would be wise to pay attention to the decent volume and price spike in Time Warner (NYSE: TWX) trading early Friday morning. We’ve been on the shares since August 11th and TWX is one of the five beaten down stocks in our recent...
Feature: Go-Time for Time Warner? Trading on Insider Information. Investors would be wise to pay attention to the decent volume and price spike in Time Warner (NYSE: TWX) trading early Friday morning. We’ve been on the shares since August 11th and TWX is one of the five beaten down stocks in our recent...
Feature: Sense Holdings - Explosive Detection About to Boom.
November 14, 2005
Feature: Sense Holdings - Explosive Detection About to Boom. What’s roughly the size of a cell-phone, weighs about two pounds, will likely cost about one-fifth the price of conventional explosives detection systems, works in real-time and could well save a significant number of lives? That would be...
Feature: Sense Holdings - Explosive Detection About to Boom. What’s roughly the size of a cell-phone, weighs about two pounds, will likely cost about one-fifth the price of conventional explosives detection systems, works in real-time and could well save a significant number of lives? That would be...
Feature: Rally Time - A Look at Tech, Oil and Housing.
November 12, 2005
Feature: Rally Time - A Look at Tech, Oil and Housing. If you get all of your investment information from the press and CNBC, you have a right to be confused. When oil was at $70 post Katrina, the conventional wisdom espoused that the price for oil and natural gas was going higher—much higher. We strongly...
Feature: Rally Time - A Look at Tech, Oil and Housing. If you get all of your investment information from the press and CNBC, you have a right to be confused. When oil was at $70 post Katrina, the conventional wisdom espoused that the price for oil and natural gas was going higher—much higher. We strongly...
Feature: Novelos - FDA Meeting Soon, Radiation and the Shriners.
November 08, 2005
Feature: Novelos - FDA Meeting Soon, Radiation and the Shriners. Two recent substantive events further bolster our contention that Novelos Therapeutics (OTCBB: NVLT) deserves a place in the smallcap biotech sector of your portfolio. First, NVLT recently announced that it had been granted a meeting with...
Feature: Novelos - FDA Meeting Soon, Radiation and the Shriners. Two recent substantive events further bolster our contention that Novelos Therapeutics (OTCBB: NVLT) deserves a place in the smallcap biotech sector of your portfolio. First, NVLT recently announced that it had been granted a meeting with...
Feature: Biophan - Shares and Sector Ready to Rock?
November 05, 2005
Feature: Biophan - Shares and Sector Ready to Rock? Followers of Biophan (OTCBB: BIPH) (and longtime SmallCap Digest readers) are well aware of its impressive licensing relationship with behemoth Boston Scientific (NYSE: BSX). If not, reread our July 16th piece detailing the terms. Further, Biophan updated the state of the relationship with BSX in a release today. The recent BIPH share price pullback—which could be due in part to the recent weakness in BSX shares - looks to us to be a great risk/reward bet for grabbing some shares of Biophan ( and BSX as well) at oversold prices. I shall explain...
Feature: Biophan - Shares and Sector Ready to Rock? Followers of Biophan (OTCBB: BIPH) (and longtime SmallCap Digest readers) are well aware of its impressive licensing relationship with behemoth Boston Scientific (NYSE: BSX). If not, reread our July 16th piece detailing the terms. Further, Biophan updated the state of the relationship with BSX in a release today. The recent BIPH share price pullback—which could be due in part to the recent weakness in BSX shares - looks to us to be a great risk/reward bet for grabbing some shares of Biophan ( and BSX as well) at oversold prices. I shall explain...
Feature: Market Update. Do You Own a Toxic Smallcap?
November 01, 2005
Feature: Market Update. Do You Own a Toxic SmallCap? Today’s piece updates our market thoughts; something we are going to do weekly or so from now on. As well, we have included a discussion of how to identify and avoid smallcap companies that employ toxic financing resulting in share-price ‘death spirals...
Feature: Market Update. Do You Own a Toxic SmallCap? Today’s piece updates our market thoughts; something we are going to do weekly or so from now on. As well, we have included a discussion of how to identify and avoid smallcap companies that employ toxic financing resulting in share-price ‘death spirals...
October 2005
Feature: Housing & Energy - Living La Vida Loca?
October 28, 2005
Feature: Housing & Energy - Living La Vida Loca? Over the 25-plus years I’ve watched the markets, I am always amazed at where the money comes from for consumers to continue buying stuff, given the economic stats and rising prices. Especially with the rampant inflation in energy, healthcare, housing...
Feature: Housing & Energy - Living La Vida Loca? Over the 25-plus years I’ve watched the markets, I am always amazed at where the money comes from for consumers to continue buying stuff, given the economic stats and rising prices. Especially with the rampant inflation in energy, healthcare, housing...
Feature: NASDAQ Rally for Real? Natural Gas Bubbles. Getting Googled.
October 25, 2005
Feature: NASDAQ Rally for Real? Natural Gas Bubbles. Getting Googled. Exactly two weeks ago, we noted that should the NASDAQ hit 2016, a decent rally would follow. That rally came as the COMP hit 2025. We’ll take a gimme. And now? As we sit at just south of 2100, the question is does this recent rally...
Feature: NASDAQ Rally for Real? Natural Gas Bubbles. Getting Googled. Exactly two weeks ago, we noted that should the NASDAQ hit 2016, a decent rally would follow. That rally came as the COMP hit 2025. We’ll take a gimme. And now? As we sit at just south of 2100, the question is does this recent rally...
Trading Alert: Sense Holdings - 'Explosive' Growth.
October 19, 2005
Trading Alert: Sense Holdings - ‘Explosive’ Growth. By the end of 2005, Sense Holdings (OTCBB: SEHO) will have delivered over 100 units of its BC-300 biometric pilot authentication stations to FedEx (NYSE: FDX). If the premier courier company in the world ultimately decided to deploy this security system...
Trading Alert: Sense Holdings - ‘Explosive’ Growth. By the end of 2005, Sense Holdings (OTCBB: SEHO) will have delivered over 100 units of its BC-300 biometric pilot authentication stations to FedEx (NYSE: FDX). If the premier courier company in the world ultimately decided to deploy this security system...
Feature: Xtreme Impresses. Volatility of Eden.
October 15, 2005
Feature: Xtreme Impresses. Volatility of Eden. We last visited with Xtreme (OTCBB: XTME) on September 26th, when the shares were 14 cents. The shares hit 20 cents in the interim, closing at 18 cents on Friday. Volumes have picked up nicely and the shares continue to appear poised for a decent upside...
Feature: Xtreme Impresses. Volatility of Eden. We last visited with Xtreme (OTCBB: XTME) on September 26th, when the shares were 14 cents. The shares hit 20 cents in the interim, closing at 18 cents on Friday. Volumes have picked up nicely and the shares continue to appear poised for a decent upside...
Feature: NASDAQ Setting Up. Novelos Pullback. Coverage Changes.
October 11, 2005
Feature: NASDAQ Setting Up. Novelos Pullback. Coverage Changes. NB: Keep an eye on your email box this Friday, for a great new idea in the realm of biometrics.We think you’ll find it not only interesting but also a superior short and long-term trading opportunity. The challenging September-October market...
Feature: NASDAQ Setting Up. Novelos Pullback. Coverage Changes. NB: Keep an eye on your email box this Friday, for a great new idea in the realm of biometrics.We think you’ll find it not only interesting but also a superior short and long-term trading opportunity. The challenging September-October market...
Feature: Biocurex - Is the Best Yet to Come?
October 06, 2005
Feature: BioCurex - Is the Best Yet to Come? Long-term readers will know that we have been covering biotech BioCurex (BOCX.PK) for exactly two years. And it’s been anything but dull. We’ve stuck with it because, in our opinion, the company stands to make a profound difference in the way cancer is diagnosed...
Feature: BioCurex - Is the Best Yet to Come? Long-term readers will know that we have been covering biotech BioCurex (BOCX.PK) for exactly two years. And it’s been anything but dull. We’ve stuck with it because, in our opinion, the company stands to make a profound difference in the way cancer is diagnosed...
Feature: Universal Detection - Report Reveals Robust Growth Projections.
October 04, 2005
Feature: Universal Detection - Report Reveals Robust Growth Projections. Dropping Superclick. On the heels of our Trading Alert last week on advanced environmental monitoring company Universal Detection Technology (OTCBB: UDTT), Beacon Equity Research has released a comprehensive 15-page report on the...
Feature: Universal Detection - Report Reveals Robust Growth Projections. Dropping Superclick. On the heels of our Trading Alert last week on advanced environmental monitoring company Universal Detection Technology (OTCBB: UDTT), Beacon Equity Research has released a comprehensive 15-page report on the...
Feature: Novelos - Research Report Calls for Significant Price Rise.
October 02, 2005
Feature: Novelos - Research Report Calls For Significant Price Rise. In a recent research report published by the Cohen Independent Research Group, the current $3.50 per share price of biotech Novelos Therapeutics (OTCBB: NVLT) could more than double over the next 12 months. And that’s at the low end...
Feature: Novelos - Research Report Calls For Significant Price Rise. In a recent research report published by the Cohen Independent Research Group, the current $3.50 per share price of biotech Novelos Therapeutics (OTCBB: NVLT) could more than double over the next 12 months. And that’s at the low end...
September 2005
Trading Alert: Universal Detection Tech - Defeating Bioterrorism
September 29, 2005
Trading Alert: Universal Detection Tech - Defeating Bioterrorism. Make sure you get to know the cutting-edge, proprietary biotech solutions of Universal Detection Technology (OTCBB: UDTT). In this post 9/11, Katrina/Rita world, improving disaster preparedness—whether natural or terrorist-- has become...
Trading Alert: Universal Detection Tech - Defeating Bioterrorism. Make sure you get to know the cutting-edge, proprietary biotech solutions of Universal Detection Technology (OTCBB: UDTT). In this post 9/11, Katrina/Rita world, improving disaster preparedness—whether natural or terrorist-- has become...
Feature: Xtreme - Oversold Conditions Ripe.
September 26, 2005
Feature: Xtreme - Oversold Conditions Ripe. Back in July- specifically from July 6 to July 12, Xtreme doubled. The stock closed at $.12 on July 6, and closed at $.25 a mere six days later. The move from $.12 to $.25 might seem like no big deal, but on a percentage basis a six day double is. If the stock...
Feature: Xtreme - Oversold Conditions Ripe. Back in July- specifically from July 6 to July 12, Xtreme doubled. The stock closed at $.12 on July 6, and closed at $.25 a mere six days later. The move from $.12 to $.25 might seem like no big deal, but on a percentage basis a six day double is. If the stock...
Feature: Biophan - Rebound Imminent.
September 25, 2005
Feature: Biophan - Rebound Imminent. Love or just like it, Biophan (OTCBB: BIPH), has been old reliable in the profit column for subscribers of the SmallCap Digest. In December of ’03 when we first featured it at $.35, BIPH was completely unknown and possessed some interesting technology in the nanotechnology...
Feature: Biophan - Rebound Imminent. Love or just like it, Biophan (OTCBB: BIPH), has been old reliable in the profit column for subscribers of the SmallCap Digest. In December of ’03 when we first featured it at $.35, BIPH was completely unknown and possessed some interesting technology in the nanotechnology...
Feature: Biocurex Steps Up to New Level
September 23, 2005
Feature: Biocurex Steps Up to New Level BioCurex (BOCX.PK) steps up to new level. BioCurex, one of the Small Cap Digest’s stalwart wins, was out with a very significant news announcement pre-open today (release below). For members of the SmallCap Digest, BOCX has been Mr. Toad’s wild profit ride. Consider...
Feature: Biocurex Steps Up to New Level BioCurex (BOCX.PK) steps up to new level. BioCurex, one of the Small Cap Digest’s stalwart wins, was out with a very significant news announcement pre-open today (release below). For members of the SmallCap Digest, BOCX has been Mr. Toad’s wild profit ride. Consider...
Feature: Taking the Risk and Volatility Out of Merck.
September 18, 2005
Feature: Taking the Risk & Volatility Out of Merck Once you’ve absorbed this risk-reduction strategy, it could well be applied to almost any optionable stock, ETF or index. With the second Vioxx trial now underway, Merck (NYSE: MRK) is once again in the news. I thought it would be valuable to discuss...
Feature: Taking the Risk & Volatility Out of Merck Once you’ve absorbed this risk-reduction strategy, it could well be applied to almost any optionable stock, ETF or index. With the second Vioxx trial now underway, Merck (NYSE: MRK) is once again in the news. I thought it would be valuable to discuss...
Feature: Blowing Bubbles. Novelos Collaborates. Coverages Dropped.
September 13, 2005
Feature: Blowing Bubbles. Novelos Collaborates. Coverages Dropped. Investing rule number one: Every market corrects. Investing rule number two: Read rule number one. The ugly stepsister of the growing economy is the current obscene level of consumer debt in America. And what could well happen to that...
Feature: Blowing Bubbles. Novelos Collaborates. Coverages Dropped. Investing rule number one: Every market corrects. Investing rule number two: Read rule number one. The ugly stepsister of the growing economy is the current obscene level of consumer debt in America. And what could well happen to that...
Feature: Biophan Trends Up. Superclick Oversold?
September 09, 2005
Feature: Biophan Trends Up. Superclick Oversold? Medical device and nano-development company Biophan (OTCBB: BIPH) has made phenomenal progress since we began covering the Rochester-based company in December 2003 at 35 cents. At a current level of $2.60, even though readers have enjoyed almost a 650...
Feature: Biophan Trends Up. Superclick Oversold? Medical device and nano-development company Biophan (OTCBB: BIPH) has made phenomenal progress since we began covering the Rochester-based company in December 2003 at 35 cents. At a current level of $2.60, even though readers have enjoyed almost a 650...
Feature: Novelos - Use Pullback to Acquire Shares.
September 06, 2005
Feature: Novelos - Use Pullback to Acquire Shares. We strongly feel that the recent pullback in Novelos Therapeutics (OTCBB: NVLT) from $4.50 to $3.20—for no reason we can ascertain-- represents a great strategic opportunity for investors to accumulate shares or add to long-term positions. We haven’t...
Feature: Novelos - Use Pullback to Acquire Shares. We strongly feel that the recent pullback in Novelos Therapeutics (OTCBB: NVLT) from $4.50 to $3.20—for no reason we can ascertain-- represents a great strategic opportunity for investors to accumulate shares or add to long-term positions. We haven’t...
Feature: Katrina Crisis. The Economy. The Market.
September 02, 2005
Feature: Katrina Crisis. The Economy. The Market. As devastating and disturbing as the situation in the US Gulf area becomes, it will in our opinion, have limited long-term economic effect. I suggest that within a month, this unprecedented natural disaster will fade from the headlines, other than being...
Feature: Katrina Crisis. The Economy. The Market. As devastating and disturbing as the situation in the US Gulf area becomes, it will in our opinion, have limited long-term economic effect. I suggest that within a month, this unprecedented natural disaster will fade from the headlines, other than being...
August 2005
Feature: MIV Therapeutics - Impressive Rally. More Patents Filed.
August 30, 2005
Feature: MIV Therapeutics - Impressive Rise. More Patents Filed. In March 2005, we were already convinced of the potential for biotech and medical device company MIV Therapeutics (OTCBB: MIVT) when we Alerted the readership to the shares at 34 cents. However, even to our typically cynical eyes, the...
Feature: MIV Therapeutics - Impressive Rise. More Patents Filed. In March 2005, we were already convinced of the potential for biotech and medical device company MIV Therapeutics (OTCBB: MIVT) when we Alerted the readership to the shares at 34 cents. However, even to our typically cynical eyes, the...
Feature: Profiting From Controversy - The Vioxx Trade(s).
August 26, 2005
Feature: Profiting From Controversy - The Vioxx Trade(s). There’s little doubt that the Vioxx controversy has been bad for everyone: patients, families, Merck, (NYSE: MRK) its shareholders, the drug sector and the markets. In no way is this piece biased against those patients and families seeking redress...
Feature: Profiting From Controversy - The Vioxx Trade(s). There’s little doubt that the Vioxx controversy has been bad for everyone: patients, families, Merck, (NYSE: MRK) its shareholders, the drug sector and the markets. In no way is this piece biased against those patients and families seeking redress...
Feature: MIV Therapeutics: New High - Partial Sales Look Prudent.
August 23, 2005
Feature: MIV Therapeutics: New High - Partial Sale Looks Prudent. On June 14th, we did a piece on the coming boom in the biotech market. The Amex Biotech Index (AMEX: ^BTK) was then about 540. It’s now 613. We also featured the NASDAQ Biotech Index iShares (AMEX: IBB) at $65. They’re now $74.50. But...
Feature: MIV Therapeutics: New High - Partial Sale Looks Prudent. On June 14th, we did a piece on the coming boom in the biotech market. The Amex Biotech Index (AMEX: ^BTK) was then about 540. It’s now 613. We also featured the NASDAQ Biotech Index iShares (AMEX: IBB) at $65. They’re now $74.50. But...
Feature: Superclick Gets Pounded - Opportunity Knocks?
August 19, 2005
Feature: Superclick Gets Pounded - Opportunity Knocks? On July 26th, we noted that Superclick (OTCBB: SPCK) shares appeared oversold. Over the next couple of weeks the price firmed a bit, idled and then, a couple of days ago, selling resumed and dropped the shares to below 50 cents—a price level not...
Feature: Superclick Gets Pounded - Opportunity Knocks? On July 26th, we noted that Superclick (OTCBB: SPCK) shares appeared oversold. Over the next couple of weeks the price firmed a bit, idled and then, a couple of days ago, selling resumed and dropped the shares to below 50 cents—a price level not...
Feature: Stocks or Fixed Income - Ratio Still Bullish. Xtreme Revenue.
August 16, 2005
Feature: Stocks or Fixed Income - Ratio Still Bullish. Xtreme Revenue. Before we discuss whether it’s better to currently own stocks or fixed income, a brief recap of what you may have missed on the SCBLOG. Over the last two weeks, we’ve suggested taking partial profits in Eden Energy (OTCBB: EDNE...
Feature: Stocks or Fixed Income - Ratio Still Bullish. Xtreme Revenue. Before we discuss whether it’s better to currently own stocks or fixed income, a brief recap of what you may have missed on the SCBLOG. Over the last two weeks, we’ve suggested taking partial profits in Eden Energy (OTCBB: EDNE...
Feature: Time Warner - Breaking Down or Breaking Up.
August 11, 2005
Feature: Time Warner - Breaking Down or Breaking Up. Even though Time Warner’s (NYSE: TWX) share price performance sucks, at least management has now pretty much admitted that it sucks. And now they have Carl Icahn and his buddies to reinforce that fact. TWX investors have to be among the most patient...
Feature: Time Warner - Breaking Down or Breaking Up. Even though Time Warner’s (NYSE: TWX) share price performance sucks, at least management has now pretty much admitted that it sucks. And now they have Carl Icahn and his buddies to reinforce that fact. TWX investors have to be among the most patient...
Feature: Novelos - Phase 1/2 Results Supercharge Chemotherapy.
August 08, 2005
Feature: Novelos - Phase 1/2 Results Supercharge Chemotherapy. If you or a loved one were suffering from late stage Non Small Cell Lung Cancer (NSCLC) would the administration of an inexpensive, complementary therapy that would allow more cycles of chemo and a better result than that from chemo alone...
Feature: Novelos - Phase 1/2 Results Supercharge Chemotherapy. If you or a loved one were suffering from late stage Non Small Cell Lung Cancer (NSCLC) would the administration of an inexpensive, complementary therapy that would allow more cycles of chemo and a better result than that from chemo alone...
Feature: Big Caps or Small Caps? What to Do.
August 04, 2005
Feature: Big Caps or Small Caps? What to do… As markets flirt with or hit 4-year highs, at least on some market indices, the question arises: should investors be buying big cap or small cap stocks? We had a tech look at three indexes and the answer appears fairly clear. If you don’t have a smallcap...
Feature: Big Caps or Small Caps? What to do… As markets flirt with or hit 4-year highs, at least on some market indices, the question arises: should investors be buying big cap or small cap stocks? We had a tech look at three indexes and the answer appears fairly clear. If you don’t have a smallcap...
Trading Alert: Novelos - Compounds Beat Up On Cancer and Hepatitis.
August 01, 2005
Trading Alert: Novelos - Compounds Beat Up On Cancer and Hepatitis. Before we detail the amazing potential of the cancer/hepatitis fighting therapies developed by Massachusetts-based Novelos Therapeutics (OTCBB: NVLT), we thought that as a reference, it would be of value to table our past smallcap biotech...
Trading Alert: Novelos - Compounds Beat Up On Cancer and Hepatitis. Before we detail the amazing potential of the cancer/hepatitis fighting therapies developed by Massachusetts-based Novelos Therapeutics (OTCBB: NVLT), we thought that as a reference, it would be of value to table our past smallcap biotech...
July 2005
Feature: Why You Need to Own Biotech. And Soon.
July 28, 2005
Feature: Why You Need To Own Biotech. And Soon. We are putting the final touches to an extremely interesting and, we believe, potentially very profitable biotech company idea—which we are planning to have in your email box after the close Monday next. We are confident that this Phase I/II Company has...
Feature: Why You Need To Own Biotech. And Soon. We are putting the final touches to an extremely interesting and, we believe, potentially very profitable biotech company idea—which we are planning to have in your email box after the close Monday next. We are confident that this Phase I/II Company has...
Feature: Superclick - Selling Overdone. Xtreme - Big Time Deal.
July 26, 2005
Feature: Superclick - Selling Overdone. Xtreme - Big Time Deal. Over the last couple of weeks, the shares of internet solutions company Superclick (OTCBB: SPCK) declined nearly 40 percent for no substantive reason that we can ascertain. We think there is a great opportunity to pick up shares at these...
Feature: Superclick - Selling Overdone. Xtreme - Big Time Deal. Over the last couple of weeks, the shares of internet solutions company Superclick (OTCBB: SPCK) declined nearly 40 percent for no substantive reason that we can ascertain. We think there is a great opportunity to pick up shares at these...
Feature: Biocurex - The Word is Out.
July 23, 2005
Feature: BioCurex - The Word is Out. SmallCap Digest is pleased to make available --to current as well as new subscribers-- an extremely detailed 24-page research report on the current and future prospects for one of our favorite biotech companies, BioCurex Inc (BOCX.PK). To acquire your online copy...
Feature: BioCurex - The Word is Out. SmallCap Digest is pleased to make available --to current as well as new subscribers-- an extremely detailed 24-page research report on the current and future prospects for one of our favorite biotech companies, BioCurex Inc (BOCX.PK). To acquire your online copy...
Feature: Biophan/BSX Details. Biotech Booms. Drugs Loom.
July 16, 2005
Feature: Biophan/BSX Details. Biotech Booms. Drugs Loom. As a backdrop against some great Biophan news—more on that in a moment—we thought it would be useful to update our views on the biotech market and take a moment to discuss the drug sector as a constituent within the sector. We think you’ll find...
Feature: Biophan/BSX Details. Biotech Booms. Drugs Loom. As a backdrop against some great Biophan news—more on that in a moment—we thought it would be useful to update our views on the biotech market and take a moment to discuss the drug sector as a constituent within the sector. We think you’ll find...
Feature: BioCurex Awakens. Tracking Eden's Volatility.
July 13, 2005
Feature: BioCurex Awakens. Tracking Eden’s Volatility. Eden Energy (OTCBB: EDNE) shares have, to say the least, had an active few days. After running up to $4.59 on Monday from under $3 last week, the shares pulled back to just under $4 Tuesday and closed the day at $4.24. Whether the rise is a result...
Feature: BioCurex Awakens. Tracking Eden’s Volatility. Eden Energy (OTCBB: EDNE) shares have, to say the least, had an active few days. After running up to $4.59 on Monday from under $3 last week, the shares pulled back to just under $4 Tuesday and closed the day at $4.24. Whether the rise is a result...
Feature: Eden Screams. Xtreme's Tide Ready to Rise.
July 08, 2005
Feature: Eden Screams. Xtreme’s Tide Ready to Rise. Although different types of companies, we feel that both of these stocks deserve your focused attention. Let’s begin with a technical look at the very undervalued recreational/Homeland Security watercraft concern Xtreme (OTCBB: XTME). Following, we...
Feature: Eden Screams. Xtreme’s Tide Ready to Rise. Although different types of companies, we feel that both of these stocks deserve your focused attention. Let’s begin with a technical look at the very undervalued recreational/Homeland Security watercraft concern Xtreme (OTCBB: XTME). Following, we...
Trading Alert: Nokia - The Knockout Punch.
July 05, 2005
Trading Alert: Nokia - The Knockout Punch. There’s little doubt that competition in the phone/pda/music/camera device market is particularly vicious. The volatility in the likes of Motorola (NYSE: MOT), Research in Motion (NASDAQ: RIMM) and even Apple (NASDAQ: APPL) is testament to all of the jockeying...
Trading Alert: Nokia - The Knockout Punch. There’s little doubt that competition in the phone/pda/music/camera device market is particularly vicious. The volatility in the likes of Motorola (NYSE: MOT), Research in Motion (NASDAQ: RIMM) and even Apple (NASDAQ: APPL) is testament to all of the jockeying...
June 2005
Feature: Volatile Markets Provide Opportunity.
June 30, 2005
Feature: Volatile Markets Provide Opportunity. In this challenging market—read here or on the SCBLOG for our most recent market call—there are definitely opportunities. Today’s are in oil, cable and internet service management. Eden Energy; Billions of barrel potential. I’ve noticed a pick-up in articles...
Feature: Volatile Markets Provide Opportunity. In this challenging market—read here or on the SCBLOG for our most recent market call—there are definitely opportunities. Today’s are in oil, cable and internet service management. Eden Energy; Billions of barrel potential. I’ve noticed a pick-up in articles...
Feature: Breaking Down the Market's Current. Oil and Interest Rates.
June 27, 2005
Feature: Breaking Down the Market's Current. Oil and Interest Rates. Thankfully, I’m not an economist. I’m just a guy who, along with our team of experienced financially oriented folk watches markets and comments on interesting stocks, trading strategies and financial trends of interest for the benefit...
Feature: Breaking Down the Market's Current. Oil and Interest Rates. Thankfully, I’m not an economist. I’m just a guy who, along with our team of experienced financially oriented folk watches markets and comments on interesting stocks, trading strategies and financial trends of interest for the benefit...
Feature: Once Around the Stable - Biophan, Biocurex et al...
June 22, 2005
Feature: Once Around the Stable - Biophan, BioCurex et al… Received some great emails on our educational/big cap strategy pieces over the last week. We like to mix it up a bit so if you have any market topics you’d like to see us cover—no matter how basic you may think they are-- send ‘em in here. Or...
Feature: Once Around the Stable - Biophan, BioCurex et al… Received some great emails on our educational/big cap strategy pieces over the last week. We like to mix it up a bit so if you have any market topics you’d like to see us cover—no matter how basic you may think they are-- send ‘em in here. Or...
Feature: Superclick Sales Soar. Russell Microcap Index to Debut.
June 20, 2005
Feature: Superclick Sales Soar. Russell Microcap Index to Debut. This Friday, the Russell family of indices will add the Russell Microcap Index. I’m excited. It looks pretty darned nifty. Expect there will be an Exchange Traded Fund (ETF) based on it, but just as we haven’t seen a symbol for the new...
Feature: Superclick Sales Soar. Russell Microcap Index to Debut. This Friday, the Russell family of indices will add the Russell Microcap Index. I’m excited. It looks pretty darned nifty. Expect there will be an Exchange Traded Fund (ETF) based on it, but just as we haven’t seen a symbol for the new...
Feature: Exchange Traded Funds
June 17, 2005
Feature: Exchange Traded Funds "Get Smart". It was bound to happen. With north of 160 Exchange Traded Funds (ETF) trading out there on virtually ever country, index and industry group, you knew that someone had to do them one better. The new “Smart’ ETF’s (known as XTF’s) may have done just that by...
Feature: Exchange Traded Funds "Get Smart". It was bound to happen. With north of 160 Exchange Traded Funds (ETF) trading out there on virtually ever country, index and industry group, you knew that someone had to do them one better. The new “Smart’ ETF’s (known as XTF’s) may have done just that by...
Feature: Biotech - The Next Big Boom?
June 14, 2005
Feature: Biotech - The Next Big Boom? For the most part, Biotech companies don’t trade on fundamentals. They are trade on the three ‘P’s”: potential, pipeline and vision. OK, two p’s and a v. Even senior companies’ prices--such as Genentech (NYSE: DNA) --look positively goofy if you try to rationalize...
Feature: Biotech - The Next Big Boom? For the most part, Biotech companies don’t trade on fundamentals. They are trade on the three ‘P’s”: potential, pipeline and vision. OK, two p’s and a v. Even senior companies’ prices--such as Genentech (NYSE: DNA) --look positively goofy if you try to rationalize...
Feature: Intel - Sold it. Bought it. Holding it.
June 10, 2005
Feature: Intel - Sold it, Bought it, Holding it. On August 12th 2004, we reversed our longstanding dislike of Intel (NASDAQ: INTC) when the shares hit $21.24. Previously we had disliked it at $34 and $28 as overvalued and over-hyped by analysts who told us to buy at the high and sell at the low. As...
Feature: Intel - Sold it, Bought it, Holding it. On August 12th 2004, we reversed our longstanding dislike of Intel (NASDAQ: INTC) when the shares hit $21.24. Previously we had disliked it at $34 and $28 as overvalued and over-hyped by analysts who told us to buy at the high and sell at the low. As...
Feature: Bio Advances - Biophan, MIV Therapeutics. Stream's Revenue
June 07, 2005
Feature: Bio Advances - Biophan, MIV Therapeutics. Stream's Revenue Flows. Biophan (OTCBB: BIPH) CEO Michael Weiner recently stated: “There is no longer any excuse for not making and certifying devices to be safe with MRI machines.” And he should know. Biophan now holds 127 issued or pending US patents...
Feature: Bio Advances - Biophan, MIV Therapeutics. Stream's Revenue Flows. Biophan (OTCBB: BIPH) CEO Michael Weiner recently stated: “There is no longer any excuse for not making and certifying devices to be safe with MRI machines.” And he should know. Biophan now holds 127 issued or pending US patents...
Feature: Biocurex's RECAF Marker - The World is Waiting.
June 03, 2005
Feature: BioCurex’s RECAF Marker - The World is Waiting. For several days in September, in Rhodes Greece, the elite of the oncology community—academia and industry—will gather at the 33rd congress of the International Society of Oncodevelopmental Biology and Medicine (ISOBM). This prestigious event...
Feature: BioCurex’s RECAF Marker - The World is Waiting. For several days in September, in Rhodes Greece, the elite of the oncology community—academia and industry—will gather at the 33rd congress of the International Society of Oncodevelopmental Biology and Medicine (ISOBM). This prestigious event...
May 2005
Feature: Biophan - Full Steam Ahead.
May 27, 2005
Feature: Biophan - Full Steam Ahead. Biophan (OTCBB: BIPH), A Company we first initiated coverage on at a mere $.35 cents back in December of 2003, has been one of the SmallCap Digest’s best performers to date yielding nearly a 600% return since we first published on this unique story. For those of...
Feature: Biophan - Full Steam Ahead. Biophan (OTCBB: BIPH), A Company we first initiated coverage on at a mere $.35 cents back in December of 2003, has been one of the SmallCap Digest’s best performers to date yielding nearly a 600% return since we first published on this unique story. For those of...
Feature: MIV Therapeutics - Implanting Life Saving Solutions.
May 23, 2005
Feature: MIV Therapeutics - Implanting Life Saving Solutions. Heart disease is, unfortunately, a growth industry, Three percent of baby boomers currently have heart disease and that number is expected to grow 10-15 percent within that demographic over the next 10 years. That’s more than 500,000 new...
Feature: MIV Therapeutics - Implanting Life Saving Solutions. Heart disease is, unfortunately, a growth industry, Three percent of baby boomers currently have heart disease and that number is expected to grow 10-15 percent within that demographic over the next 10 years. That’s more than 500,000 new...
Feature: Biocurex Expands RECAF Technologies.
May 20, 2005
Feature: BioCurex Expands RECAF Technologies. As we noted in our May 11th article, BioCurex (BOCK.PK) is expanding its cancer imaging and therapy technology focus. With the announcement (release below) of a collaboration with the Goshen, Indiana-based Center for Cancer Care, the Company already appears...
Feature: BioCurex Expands RECAF Technologies. As we noted in our May 11th article, BioCurex (BOCK.PK) is expanding its cancer imaging and therapy technology focus. With the announcement (release below) of a collaboration with the Goshen, Indiana-based Center for Cancer Care, the Company already appears...
Feature: Eden Energy - Got Oil? If Not, Best Get Some. Now.
May 17, 2005
Feature: Eden Energy - Got Oil? If Not, Best Get Some. Now. I simply do not believe that there is currently enough oil to meet future global demand—at least not at these prices. No matter how many talking heads and ‘industry analysts’ espouse that the supply situation isn’t critical, it is. Our national...
Feature: Eden Energy - Got Oil? If Not, Best Get Some. Now. I simply do not believe that there is currently enough oil to meet future global demand—at least not at these prices. No matter how many talking heads and ‘industry analysts’ espouse that the supply situation isn’t critical, it is. Our national...
Feature: MIV Therapeutics - Stalking a Killer.
May 13, 2005
Feature: MIV Therapeutics - Stalking a killer. Strokes are the third leading cause of death and THE leading cause of disability. That fact alone, in our opinion, makes the work and investment potential of MIV Therapeutics (OTCBB: MIVT) even more compelling. Technological improvements and advancements...
Feature: MIV Therapeutics - Stalking a killer. Strokes are the third leading cause of death and THE leading cause of disability. That fact alone, in our opinion, makes the work and investment potential of MIV Therapeutics (OTCBB: MIVT) even more compelling. Technological improvements and advancements...
Feature: Biocurex - The Year Ahead: Hunter, Killer.
May 11, 2005
Feature: BioCurex - The Year Ahead: Hunter, Killer. When we first brought BioCurex (BOCX.PK) to the readership at 17 cents in October of 2003, it was an interesting little biotech with the promise of technologies that we felt could revolutionize the early detection of cancer. And for those who have...
Feature: BioCurex - The Year Ahead: Hunter, Killer. When we first brought BioCurex (BOCX.PK) to the readership at 17 cents in October of 2003, it was an interesting little biotech with the promise of technologies that we felt could revolutionize the early detection of cancer. And for those who have...
Feature: Superclick Checks into Fairmont Hotel Chain.
May 05, 2005
Feature: Superclick Checks into Fairmont Hotel Chain. With 23 Fairmont Hotel properties already equipped with Superclick’s (OTCBB: SPCK) Internet Management System (SIMS), it’s apparent that the company’s Internet access solutions are gaining quality ground, and fast. Fairmont owns and operates 83 properties...
Feature: Superclick Checks into Fairmont Hotel Chain. With 23 Fairmont Hotel properties already equipped with Superclick’s (OTCBB: SPCK) Internet Management System (SIMS), it’s apparent that the company’s Internet access solutions are gaining quality ground, and fast. Fairmont owns and operates 83 properties...
Feature: Stream-ing Higher Revenues.
May 04, 2005
Feature: Stream-ing Higher Revenues Business and revenue growth continuing nicely, thank-you. Stream Communications (OTCBB: SCNWF) 2004 annual revenues surpassed 2003 (release below) by almost 20 percent to C$4.42 million ($3.5 million). The company feels that with the current subscriber base, annualized...
Feature: Stream-ing Higher Revenues Business and revenue growth continuing nicely, thank-you. Stream Communications (OTCBB: SCNWF) 2004 annual revenues surpassed 2003 (release below) by almost 20 percent to C$4.42 million ($3.5 million). The company feels that with the current subscriber base, annualized...
April 2005
Trading Alert: Eden Energy - Elephants on The Horizon.
April 26, 2005
Trading Alert: Eden Energy - Elephants on The Horizon. Let’s cut to the chase. Limited alternative energy sources aside, the world still needs more oil and gas—a lot more. The crude oil price is rising and, with minor pullbacks, will likely continue to appreciate. Global production levels are in decline...
Trading Alert: Eden Energy - Elephants on The Horizon. Let’s cut to the chase. Limited alternative energy sources aside, the world still needs more oil and gas—a lot more. The crude oil price is rising and, with minor pullbacks, will likely continue to appreciate. Global production levels are in decline...
Feature: MIV Therapeutics - The Life They Save...
April 21, 2005
Feature: MIV Therapeutics - The Life They Save… Before we chat about MIV Therapeutics (OTCBB: MIVT) and the amazing progress the company has made on its rapid journey towards commercialization, an important word about the SCBLOG—our complimentary real-time publication that delivers critical information...
Feature: MIV Therapeutics - The Life They Save… Before we chat about MIV Therapeutics (OTCBB: MIVT) and the amazing progress the company has made on its rapid journey towards commercialization, an important word about the SCBLOG—our complimentary real-time publication that delivers critical information...
Feature: MIV Validates Biocompatibility. Xtreme Floats More Boats.
April 18, 2005
Feature: MIV Validates Biocompatibility. Xtreme Floats More Boats. MIV Therapeutics (OTCBB: MIVT) issued two significant press releases late last week regarding product studies that markedly advance the importance of both its technologies as well as move it closer toward its goal of commercialization...
Feature: MIV Validates Biocompatibility. Xtreme Floats More Boats. MIV Therapeutics (OTCBB: MIVT) issued two significant press releases late last week regarding product studies that markedly advance the importance of both its technologies as well as move it closer toward its goal of commercialization...
Trading Alert: Stream - Like Buying Cable Stocks 20 Years Ago.
April 17, 2005
Trading Alert: Stream - Like Buying Cable Stocks 20 Years Ago. US Cable penetration is now 67 percent or 80 million households. In 1981, that penetration was 28 percent. Revenue for cable operators in 1985 was less than $10 billion compared to $57 billion in 2004. Projections raise that number to $86...
Trading Alert: Stream - Like Buying Cable Stocks 20 Years Ago. US Cable penetration is now 67 percent or 80 million households. In 1981, that penetration was 28 percent. Revenue for cable operators in 1985 was less than $10 billion compared to $57 billion in 2004. Projections raise that number to $86...
Feature: Biocurex - Blood Test Detects More Cancers. MarketNotes.
April 15, 2005
Feature: Biocurex - Blood Test Detects More Cancers. MarketNotes. Until a cure for cancer is found, early detection of this disease remains paramount. Biocurex (BOCX.PK) announced today (release below) that it had found that its RECAF blood test detected 92 percent of cervical cancers using only a drop...
Feature: Biocurex - Blood Test Detects More Cancers. MarketNotes. Until a cure for cancer is found, early detection of this disease remains paramount. Biocurex (BOCX.PK) announced today (release below) that it had found that its RECAF blood test detected 92 percent of cervical cancers using only a drop...
Trading Alert: Spescom - (Organizing) Knowledge is Power.
April 12, 2005
Trading Alert: Spescom - (Organizing) Knowledge is Power. There are lots of software companies. Then there’s San Diego-based Spescom Software (OTCBB: SPCO). Critical business information isn’t of much use if all types of that information aren’t organized precisely--and readily accessible. With all the...
Trading Alert: Spescom - (Organizing) Knowledge is Power. There are lots of software companies. Then there’s San Diego-based Spescom Software (OTCBB: SPCO). Critical business information isn’t of much use if all types of that information aren’t organized precisely--and readily accessible. With all the...
Feature: MIV Therapeutics - Advancing Cardiac Devices. Big Time.
April 07, 2005
Feature: MIV Therapeutics - Advancing Cardiac Devices. Big Time. MIV Therapeutic's (OTCBB: MIVT) R&D continues to deliver the goods. Thursday's release (below) details two new patents filed by the company that build on the promise of making cardiac stents and indeed a number of implantable devices...
Feature: MIV Therapeutics - Advancing Cardiac Devices. Big Time. MIV Therapeutic's (OTCBB: MIVT) R&D continues to deliver the goods. Thursday's release (below) details two new patents filed by the company that build on the promise of making cardiac stents and indeed a number of implantable devices...
Feature: Biophan - Accumulate For the Long-Term.
April 02, 2005
Feature: Biophan - Accumulate For The Long-Term. On September 25th, 2004 when we last visited with nanotech firm Biophan (OTCBB: BIPH), we suggested that investors should consider accumulating the shares at around 80-ish cents. For those who bought BIPH at that point and held, good on you. We feel that...
Feature: Biophan - Accumulate For The Long-Term. On September 25th, 2004 when we last visited with nanotech firm Biophan (OTCBB: BIPH), we suggested that investors should consider accumulating the shares at around 80-ish cents. For those who bought BIPH at that point and held, good on you. We feel that...
March 2005
Feature: Biocurex - MGMT Discusses Licensing Deal.
March 31, 2005
Feature: Biocurex - MGMT Discusses Licensing Deal. After impressive news (read our previous piece for the details) from biotech Biocurex (BOCX.PK) on Tuesday announcing an outstanding licensing agreement with Abbott Labs (NYSE: ABT) BOCX’s share price experienced significant volatility. The company...
Feature: Biocurex - MGMT Discusses Licensing Deal. After impressive news (read our previous piece for the details) from biotech Biocurex (BOCX.PK) on Tuesday announcing an outstanding licensing agreement with Abbott Labs (NYSE: ABT) BOCX’s share price experienced significant volatility. The company...
Feature: Biocurex Signs Abbott Labs - Licensing Deal Done.
March 29, 2005
Feature: Biocurex Signs Abbott Labs - Licensing Deal Done. Patience rewarded. Significant milestone achieved. Those two phrases encapsulate the importance of the joint announcement made today (release below) by biotech Biocurex (BOCX.PK) of the completion of a deal granting world-wide, semi-exclusive...
Feature: Biocurex Signs Abbott Labs - Licensing Deal Done. Patience rewarded. Significant milestone achieved. Those two phrases encapsulate the importance of the joint announcement made today (release below) by biotech Biocurex (BOCX.PK) of the completion of a deal granting world-wide, semi-exclusive...
Feature: Xtreme Delivers, Again.
March 27, 2005
Feature: Xtreme Delivers, Again. For the second time in a week, Xtreme Companies (OTCBB: XTME) has announced the sale of one of its Fire Rescue Watercraft through the Homeland Security Grant Program (HSGP) as a result of its efforts working with local and regional First Responders. On March 22nd, XTME...
Feature: Xtreme Delivers, Again. For the second time in a week, Xtreme Companies (OTCBB: XTME) has announced the sale of one of its Fire Rescue Watercraft through the Homeland Security Grant Program (HSGP) as a result of its efforts working with local and regional First Responders. On March 22nd, XTME...
Feature: A Stock In Play? More SmallCap Business Intelligence.
March 23, 2005
Feature: A Stock In Play? More SmallCap Business Intelligence. As a result of recent acquisitions and consolidations, data integrator Informatica Corp (NASDAQ: INFA) appears pretty much the only game left in town in the growing business intelligence sector. Press articles are printing rumors that this...
Feature: A Stock In Play? More SmallCap Business Intelligence. As a result of recent acquisitions and consolidations, data integrator Informatica Corp (NASDAQ: INFA) appears pretty much the only game left in town in the growing business intelligence sector. Press articles are printing rumors that this...
Feature: MIV Therapeutics - A Stroke Stopping Acquisition.
March 19, 2005
Feature: MIV Therapeutics - A Stroke Stopping Acquisition. We don’t usually publish two pieces on the same company within a week, however, substantive news can trump that practice. And this news is certainly applicable. We Alerted the readership to MIV Therapeutics (OTCBB: MIVT) last Friday with the...
Feature: MIV Therapeutics - A Stroke Stopping Acquisition. We don’t usually publish two pieces on the same company within a week, however, substantive news can trump that practice. And this news is certainly applicable. We Alerted the readership to MIV Therapeutics (OTCBB: MIVT) last Friday with the...
Feature: For My Money, CNBC IS A Mess.
March 16, 2005
Feature: For My Money, CNBC Is A Mess. Note to GE: Hire someone who actually knows something about business and investors to produce CNBC’s programming. I’ve watched this station for over 10 years and in my opinion it has consistently become less relevant. Not that the on air talent—who seem to change...
Feature: For My Money, CNBC Is A Mess. Note to GE: Hire someone who actually knows something about business and investors to produce CNBC’s programming. I’ve watched this station for over 10 years and in my opinion it has consistently become less relevant. Not that the on air talent—who seem to change...
Trading Alert: MIV Therapeutics - Superior Stents. Global Deal.
March 12, 2005
Trading Alert: MIV Therapeutics - Superior Stents. Global Deal. A few years ago, investors likely hadn’t even heard of cardiac stents. And until now, they’d likely not heard of MIV Therapeutics (OTCBB: MIVT), either. We believe this smallcap company not only has the biotechnology to eventually gain...
Trading Alert: MIV Therapeutics - Superior Stents. Global Deal. A few years ago, investors likely hadn’t even heard of cardiac stents. And until now, they’d likely not heard of MIV Therapeutics (OTCBB: MIVT), either. We believe this smallcap company not only has the biotechnology to eventually gain...
Feature: Xtreme - Takes on All Challengers.
March 09, 2005
Feature: Xtreme - Takes on all Challengers. If you needed any convincing that the recreational boat market is extremely buoyant, read our profile of MarineMax (NYSE: HZO) that we published on April 30th, 2003. The stock was $11 then, $33-plus now. And the growth of the personal boat/yacht sector shows...
Feature: Xtreme - Takes on all Challengers. If you needed any convincing that the recreational boat market is extremely buoyant, read our profile of MarineMax (NYSE: HZO) that we published on April 30th, 2003. The stock was $11 then, $33-plus now. And the growth of the personal boat/yacht sector shows...
Feature: Martha's Out. Time to Get Out.
March 04, 2005
Feature: Martha’s Out. Stock’s Out of Favor. On February 25th, and frequently on the SCBLOG, we’ve named some stocks we felt were overpriced traps that could hurt enthusiastic buyers who were either late or stayed too long at the party. The newest addition to the list is Martha Stewart’s company (NYSE...
Feature: Martha’s Out. Stock’s Out of Favor. On February 25th, and frequently on the SCBLOG, we’ve named some stocks we felt were overpriced traps that could hurt enthusiastic buyers who were either late or stayed too long at the party. The newest addition to the list is Martha Stewart’s company (NYSE...
Feature: Biocurex Rising. Company Updates.
March 01, 2005
Feature: Biocurex Rising. Company Updates. As we noted on the SCBLOG over the weekend, there appears to be something going on with the shares of Biocurex (BOCX.PK). Friday, the shares closed at $1.15, after closing at 76 cents, Thursday. Friday’s volume was north of 800,000 shares. On Monday the shares...
Feature: Biocurex Rising. Company Updates. As we noted on the SCBLOG over the weekend, there appears to be something going on with the shares of Biocurex (BOCX.PK). Friday, the shares closed at $1.15, after closing at 76 cents, Thursday. Friday’s volume was north of 800,000 shares. On Monday the shares...
February 2005
Feature: SCBLOG Saves You Money. Big Time.
February 25, 2005
Feature: SCBLOG Saves You Money. Big Time. One of the neat things about the SCBLOG is that we bring readers tips, opinions and trading ideas to not only make money, but to also help avoid those momentum traps that exhibit signs dedicated to the destruction of your trading funds. You’d be wise to get...
Feature: SCBLOG Saves You Money. Big Time. One of the neat things about the SCBLOG is that we bring readers tips, opinions and trading ideas to not only make money, but to also help avoid those momentum traps that exhibit signs dedicated to the destruction of your trading funds. You’d be wise to get...
Feature: Splitting Apple's Core. Tough Tuesday.
February 23, 2005
Feature: Splitting Apple’s Core. Tough Tuesday. You need to access our interactive SCBLOG. With automatic update availability through the simple to use RSS Feeds, the link on our homepage or in each newsletter, readers can gain access to new postings and can thereby get the latest news as well as pertinent...
Feature: Splitting Apple’s Core. Tough Tuesday. You need to access our interactive SCBLOG. With automatic update availability through the simple to use RSS Feeds, the link on our homepage or in each newsletter, readers can gain access to new postings and can thereby get the latest news as well as pertinent...
Feature: Spectrum - Another Very Big Deal, Again.
February 17, 2005
Feature: Spectrum - Another Very Big Deal, Again. On Monday, we noted Spectrum Science's (OTCBB: SPSC) announcement of its major acquisition of Canadian firm M&M Engineering. Thursday, the company announced (release below) that it has entered into a letter of intent (LOI) to acquire privately owned...
Feature: Spectrum - Another Very Big Deal, Again. On Monday, we noted Spectrum Science's (OTCBB: SPSC) announcement of its major acquisition of Canadian firm M&M Engineering. Thursday, the company announced (release below) that it has entered into a letter of intent (LOI) to acquire privately owned...
Feature: Spectrum - Acquisition Triples Revenue. No Dilution.
February 14, 2005
Feature: Spectrum - Acquisition Triples Revenues. No Dilution. Investors who’ve participated in the substantive developments at Spectrum Sciences (OTCBB: SPSC) have done well, and will likely continue to do so, courtesy of recent corporate announcements such as the company’s recent completion of its...
Feature: Spectrum - Acquisition Triples Revenues. No Dilution. Investors who’ve participated in the substantive developments at Spectrum Sciences (OTCBB: SPSC) have done well, and will likely continue to do so, courtesy of recent corporate announcements such as the company’s recent completion of its...
Feature: HP - The Goodbye Carly Trade.
February 11, 2005
Feature: HP - The Goodbye Carly Trade. More ink has been spilled on Carly Fiorina’s ouster from behemoth Hewlett Packard (NYSE: HPQ) than just about any story I’ve ever seen. Most lament that she’s a woman (like that matters)or that she was wrong for the job or she had vision but couldn’t execute, yadda...
Feature: HP - The Goodbye Carly Trade. More ink has been spilled on Carly Fiorina’s ouster from behemoth Hewlett Packard (NYSE: HPQ) than just about any story I’ve ever seen. Most lament that she’s a woman (like that matters)or that she was wrong for the job or she had vision but couldn’t execute, yadda...
Trading Alert: Micromuse - Cash Mountain. No Debt. Great Prospects.
February 09, 2005
Trading Alert: Micromuse - Cash Mountain. No Debt. Great Prospects. By the way, keep tuned to the SCBLOG for updates, trading ideas and opinion. The latest on Spectrum and others, for example… join the thousands of folks who use the SCBLOG to stay informed. Readers of the SmallCap Digest will know that...
Trading Alert: Micromuse - Cash Mountain. No Debt. Great Prospects. By the way, keep tuned to the SCBLOG for updates, trading ideas and opinion. The latest on Spectrum and others, for example… join the thousands of folks who use the SCBLOG to stay informed. Readers of the SmallCap Digest will know that...
Feature: Force Protection Does the Splits.
February 04, 2005
Feature: Force Protection Does the Splits. Force Protection (OTCBB: FRPT) announced Thursday evening that as of the open today, Friday, it would reverse split its shares 12 for 1. Investors need to adjust their positions—for example, if you had 12000 ‘old’ shares, you now have 1000 ‘new’—and trade accordingly...
Feature: Force Protection Does the Splits. Force Protection (OTCBB: FRPT) announced Thursday evening that as of the open today, Friday, it would reverse split its shares 12 for 1. Investors need to adjust their positions—for example, if you had 12000 ‘old’ shares, you now have 1000 ‘new’—and trade accordingly...
Feature: Payment Data - More Deals. Sector Heating Up.
February 01, 2005
Feature: Payment Data - More Deals. Sector Heating Up. We Alerted the readership to payment solutions provider Payment Data Systems (OTCBB: PYDS) on November 12th. Since then, the company’s corporate progress has been nothing short of outstanding. Substantive deals announced, new revenue streams opened...
Feature: Payment Data - More Deals. Sector Heating Up. We Alerted the readership to payment solutions provider Payment Data Systems (OTCBB: PYDS) on November 12th. Since then, the company’s corporate progress has been nothing short of outstanding. Substantive deals announced, new revenue streams opened...
January 2005
Feature: Superclick Exceeds 2004 Revenue Guidance.
January 28, 2005
Feature: Superclick Exceeds 2004 Revenue Guidance. I'll make this really simple. For full year (FY) 2003, Internet solutions provider Superclick (OTCBB: SPCK) did revenues of around $650,000. For the full year (FY) 2004, the company has announced (release below) revenues of nearly $2.8 million. That’s...
Feature: Superclick Exceeds 2004 Revenue Guidance. I'll make this really simple. For full year (FY) 2003, Internet solutions provider Superclick (OTCBB: SPCK) did revenues of around $650,000. For the full year (FY) 2004, the company has announced (release below) revenues of nearly $2.8 million. That’s...
Feature: Force Protection - Fighting Fit.
January 24, 2005
Feature: Force Protection - Fighting Fit. As we have oft-mentioned, Force Protection (OTCBB: FRCP) is a smallcap company in the right sector at the right time. After the close Friday, the company announced (http://biz.yahoo.com/bw/050121/215496_1.html) a significant financing deal—roughly $16 million...
Feature: Force Protection - Fighting Fit. As we have oft-mentioned, Force Protection (OTCBB: FRCP) is a smallcap company in the right sector at the right time. After the close Friday, the company announced (http://biz.yahoo.com/bw/050121/215496_1.html) a significant financing deal—roughly $16 million...
Feature: Superclick Wires Europe
January 20, 2005
Feature: Superclick Wires Europe. As today’s announcement (release below) evidences, Internet access concern Superclick (OTCBB: SPCK) is taking Europe. The company’s relationship with Europe’s leading VOD (Video on Demand) integrator, Locatel, has been consummated. Big time. We first brought you the...
Feature: Superclick Wires Europe. As today’s announcement (release below) evidences, Internet access concern Superclick (OTCBB: SPCK) is taking Europe. The company’s relationship with Europe’s leading VOD (Video on Demand) integrator, Locatel, has been consummated. Big time. We first brought you the...
Feature: Apple - iCame, iSaw, iPaused.
January 14, 2005
Feature: Apple - iCame, iSaw, iPaused. Always get lots of email when I do a piece on Apple (NASDAQ: AAPL). For the product faithful, --of which I am one—no worries, I’m not going to diss the company, but for the rational, there are some things that need to be discussed if you’re a shareholder or thinking...
Feature: Apple - iCame, iSaw, iPaused. Always get lots of email when I do a piece on Apple (NASDAQ: AAPL). For the product faithful, --of which I am one—no worries, I’m not going to diss the company, but for the rational, there are some things that need to be discussed if you’re a shareholder or thinking...
Feature: Reverse Splits - Less Can Be More.
January 12, 2005
Feature: Reverse Splits - Less can be more. Historically, a number of companies that employ a reverse split strategy tend to see their shares do better price-wise immediately after the split than in the longer term. Mainly because a lot of reverse splits are done only for cosmetic reasons and bring...
Feature: Reverse Splits - Less can be more. Historically, a number of companies that employ a reverse split strategy tend to see their shares do better price-wise immediately after the split than in the longer term. Mainly because a lot of reverse splits are done only for cosmetic reasons and bring...
Feature: Smallcaps in 2005 - History Doesn't Lie.
January 07, 2005
Feature: Smallcaps in 2005 - History doesn’t lie. Especially when one looks at the benchmark smallcap index, the Russell 2000--more on that in a moment. I receive lots of mail asking about our criteria for picking stocks. It’s pretty simple actually. First, though not foremost, companies that make the...
Feature: Smallcaps in 2005 - History doesn’t lie. Especially when one looks at the benchmark smallcap index, the Russell 2000--more on that in a moment. I receive lots of mail asking about our criteria for picking stocks. It’s pretty simple actually. First, though not foremost, companies that make the...
Feature: A Happy New Year, for Isonics, Spectrum. Already.
January 05, 2005
Feature: A Happy New Year, for Isonics, Spectrum. Already. I don’t actually subscribe to the theory that as the first week of January goes, so goes the year. But, for a couple of names in our stable, the first week of 2005 may indeed evidence some bon temps ahead. As I have mentioned previously on the...
Feature: A Happy New Year, for Isonics, Spectrum. Already. I don’t actually subscribe to the theory that as the first week of January goes, so goes the year. But, for a couple of names in our stable, the first week of 2005 may indeed evidence some bon temps ahead. As I have mentioned previously on the...